A. Goy
Molecular Biology · 2006–2020
A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 28 citations into it
Whom A. Goy trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Ronald C. Taylor (in Molecular Biology)
Papers from A. Goy's perspective
Ordered by how strongly the researchers A. Goy trusts endorse each paper. Same corpus, a different order for every researcher.
- Diagnostic error in internal medicine. (Archives of Internal Medicine)
- Building Watson: An Overview of the DeepQA Project
- The value of health care information exchange and interoperability. (Health Affairs)
- Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. (Archives of Internal Medicine)
- Definition, structure, content, use and impacts of electronic health records: A review of the research literature (Int. J. Medical Informatics)
- Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (Cancer Discovery)
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. (Blood)
- Medication-related clinical decision support in computerized provider order entry systems: a review. (JAMIA Journal of the American Medical Informatics Association)
- Network Medicine: A Network-based Approach to Human Disease
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial (The Lancet Oncology)
Their papers
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma (2014) — 1,040 citations
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. (2020) — 1,403 citations
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. (2020) — 658 citations
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial (2018) — 1,782 citations
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (2017) — 4,882 citations
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma (2015) — 1,094 citations
- Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine (2015) — 350 citations
- Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. (2015) — 1,473 citations
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma (2013) — 1,598 citations
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. (2011) — 609 citations
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006) — 734 citations